Eli Lilly and Company announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Donanemab met the primary endpoint of...
CREDIT: Dan Addison | University of Virginia Communications UVA Health researchers have discovered a molecule in the brain responsible for orchestrating the immune system’s responses to Alzheimer’s disease and multiple sclerosis (MS), potentially allowing doctors to...
Rather than attempting to treat the multiple pathologies of Alzheimer’s disease individually, as is the current practice, researchers in the Buck Institute’s Andersen lab have designed a smart cell-based delivery system (SmaCD) to treat them all at once. The National...
